000304582 001__ 304582
000304582 005__ 20250916115009.0
000304582 0247_ $$2doi$$a10.1136/jitc-2025-012747
000304582 0247_ $$2pmid$$apmid:40940136
000304582 037__ $$aDKFZ-2025-01905
000304582 041__ $$aEnglish
000304582 082__ $$a610
000304582 1001_ $$00000-0002-2428-6109$$aRegan, Meredith M$$b0
000304582 245__ $$aAnalysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
000304582 260__ $$aLondon$$bBioMed Central$$c2025
000304582 3367_ $$2DRIVER$$aarticle
000304582 3367_ $$2DataCite$$aOutput Types/Journal article
000304582 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757942277_16521
000304582 3367_ $$2BibTeX$$aARTICLE
000304582 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304582 3367_ $$00$$2EndNote$$aJournal Article
000304582 520__ $$aTreatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab. This analysis compared TFS for nivolumab plus relatlimab and nivolumab monotherapy in patients with advanced melanoma.Data were from 714 patients in the phase 2/3 RELATIVITY-047 trial (ClinicalTrials.gov identifier: NCT03470922). TFS was defined as the difference in restricted mean event times between the Kaplan-Meier curves for time to protocol therapy cessation and time to subsequent systemic anticancer therapy initiation or death. TFS was further partitioned into time with and time without grade ≥3 treatment-related adverse events (TRAEs). Subgroup analysis based on tumor BRAF mutational status and tumor programmed death ligand 1 (PD-L1) expression level was conducted. Between-treatment group differences were calculated with bootstrapped 95% CIs.At 48 months from randomization, Kaplan-Meier estimates of overall survival were 52% and 43% for patients in the nivolumab plus relatlimab and nivolumab groups, respectively; 38% and 33% of patients in these respective groups were free of subsequent systemic therapy. The 48-month mean TFS was 2.9 months (95% CI 1.0 to 4.9) longer with nivolumab plus relatlimab than with nivolumab (9.7 vs 6.8 months, respectively). Mean TFS represented 20% and 14% of the 48-month period after initiating nivolumab plus relatlimab and nivolumab, respectively. Considering only time without grade ≥3 TRAEs, the 48-month mean TFS was 2.6 months (95% CI 0.8 to 4.5) longer with nivolumab plus relatlimab than with nivolumab (9.1 vs 6.5 months, respectively). The 48-month mean total TFS was consistently longer with nivolumab plus relatlimab than with nivolumab in the BRAF mutant (9.4 vs 6.5 months), BRAF wild-type (9.9 vs 6.9 months), PD-L1 ≥1% (12.3 vs 7.7 months), and PD-L1<1% (7.9 vs 6.2 months) subgroups.This analysis demonstrated TFS benefit during the 48 months since initiating nivolumab plus relatlimab compared with nivolumab alone in patients with advanced melanoma. A direct comparison between nivolumab plus relatlimab and nivolumab plus ipilimumab is needed to determine the differences between the regimens in TFS and those in traditional endpoints.
000304582 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304582 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304582 650_7 $$2Other$$aImmune Checkpoint Inhibitor
000304582 650_7 $$2Other$$aImmunotherapy
000304582 650_7 $$2Other$$aSkin Cancer
000304582 7001_ $$00000-0002-8322-475X$$aAscierto, Paolo A$$b1
000304582 7001_ $$00000-0003-2976-0911$$aLipson, Evan J$$b2
000304582 7001_ $$aPalaia, Jennell$$b3
000304582 7001_ $$aMoshyk, Andriy$$b4
000304582 7001_ $$aSelvan, Abraham$$b5
000304582 7001_ $$aLao, Christopher D$$b6
000304582 7001_ $$00000-0003-3901-9924$$aAtkins, Michael B$$b7
000304582 7001_ $$00000-0002-2675-5095$$aMcDermott, David F$$b8
000304582 7001_ $$aPotluri, Ravi$$b9
000304582 7001_ $$aRanjan, Sandip$$b10
000304582 7001_ $$aBilthare, Sandeep$$b11
000304582 7001_ $$00000-0001-8894-3545$$aLong, Georgina V$$b12
000304582 7001_ $$aStephen Hodi, F.$$b13
000304582 7001_ $$00000-0003-1942-851X$$aTawbi, Hussein$$b14
000304582 7001_ $$00000-0003-3524-7858$$aSchadendorf, Dirk$$b15
000304582 773__ $$0PERI:(DE-600)2719863-7$$a10.1136/jitc-2025-012747$$gVol. 13, no. 9, p. e012747 -$$n9$$pe012747$$tJournal for ImmunoTherapy of Cancer$$v13$$x2051-1426$$y2025
000304582 909CO $$ooai:inrepo02.dkfz.de:304582$$pVDB
000304582 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-3524-7858$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000304582 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304582 9141_ $$y2025
000304582 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ IMMUNOTHER CANCER : 2022$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-24T13:16:43Z
000304582 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-24T13:16:43Z
000304582 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-01-24T13:16:43Z
000304582 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ IMMUNOTHER CANCER : 2022$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000304582 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000304582 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304582 980__ $$ajournal
000304582 980__ $$aVDB
000304582 980__ $$aI:(DE-He78)ED01-20160331
000304582 980__ $$aUNRESTRICTED